We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Veronika Bachanova

Veronika Bachanova MD

Assistant Professor, Hematology & Oncology, University of Minnesota, Minneapolis, Minnesota

Dr. Bachanova received her MD degree from Komenius University Medical School in Slovakia in 1992. She joined the National Cancer Institute in Bratislava, Slovakia to train in Oncology and Supportive Care. She received her PhD at the School of Public Health in Slovakia in 1997. She has lived and worked in the US since 1995. Dr. Bachanova completed an internal medicine residency at the Henry Ford Hospital and became a Hematology and Oncology fellow at the University of Minnesota in 2004.  Her basic research in the areas of natural killer cell development and immunobiology during her training led to several prestigious awards including the Young ASCO Investigator Award, CALGB Clinical Investigator award and the best basic science article by a new investigator in Biology of Blood and Marrow Transplantation. She is a recipient of the American Society of Hematology Junior Scholar Award.

Dr. Bachanova joined the faculty at the University of Minnesota in 2007. Her research and clinical work focus is in stem cell transplantation and therapy for hematologic malignancies. She leads the Lymphoma Interdisciplinary team at UM, co-directs the leukemia tissue bank and is a principal investigator on over a dozen clinical trials. She leads the development of immunotherapy trials for lymphoma using natural killer cells and antibody therapies and has active collaborations with basic researchers to translate new therapies to the clinic.